Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (formerly Hybridoma), presents the latest developments in characterization and application of mAbs and publishes descriptions and resources of novel mAbs. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy’s targeted coverage advances our understanding of immune responses and is an essential resource on the use of immunological methods for experimental and therapeutic purposes for researchers and clinicians in immunology and cancer biology.
Fully refereed, peer-reviewed articles and short communications present current findings in the development and characterization of mAbs across all therapeutic areas. Development of mAbs for all research applications, including probes, inhibitors, and diagnostic reagents, is also described.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy covers:
- Isolation and production methods
- Characterization, epitope mapping
- Delivery systems for immunotherapeutic and experimental purposes
- Application of mAbs to elucidate signaling pathways
- Development of immunotherapeutic compounds
- Generation of probes for molecular monitoring
- Creation of diagnostic reagents, experimental and clinical
- Analysis of mAb antagonistic/inhibitory effects
- Cellular and molecular responses to mAb immunization
- Immunoscreening for identification of molecular variants and markers
- New sources for availability of fully characterized mAbs
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy is under the editorial leadership of Editor Zenon Steplewski, Biotechnology Foundation Inc., Philadelphia, PA, and other leading investigators. View the entire editorial board.
Audience: Cell biologists, immunologists, molecular biologists, among others
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.